Epidemiology of HPV infection and current status of cervical cancer prevention in Greece: final results of the LYSISTRATA cross-sectional study
| Autor: | Theodoros, Agorastos, Kimon, Chatzistamatiou, Menelaos, Zafrakas, Vagia, Siamanta, Taxiarchis, Katsamagkas, Theodoros C, Constantinidis, Alexandros F, Lampropoulos |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Cancer Research medicine.medical_specialty Epidemiology Cross-sectional study Papanicolaou stain Uterine Cervical Neoplasms Young Adult medicine Prevalence Secondary Prevention Humans Papillomavirus Vaccines Prospective Studies Papillomaviridae Prospective cohort study Early Detection of Cancer Cervical cancer Gynecology Vaginal Smears biology Greece Obstetrics business.industry Papillomavirus Infections Public Health Environmental and Occupational Health HPV infection Middle Aged biology.organism_classification medicine.disease Prognosis Vaccination Cross-Sectional Studies Oncology DNA Viral Female business Follow-Up Studies |
| Zdroj: | European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP). 23(5) |
| ISSN: | 1473-5709 |
| Popis: | The objective of this study was to assess the overall prevalence of the human papilloma virus (HPV) infection and distribution of high-risk HPV (hrHPV) types in Greece and evaluate the participation of women in primary and secondary cervical cancer prevention. This was a prospective, cross-sectional study carried out between October 2005 and January 2011 in Greece; 5379 women filled out the study questionnaire anonymously. 5107 women underwent cervical HPV-DNA testing, either by Hybrid Capture 2, followed by restriction fragment length polymorphism-PCR, or by the Abbott Real-Time High-Risk HPV test. Overall, 5.8% (295/5107) of women were positive for hrHPV infection. The most common hrHPV type was HPV-16 (24.8% among infected women; 1.4% overall), followed by HPV types 31, 35, 53, 18, 51, 56, 58, 52, 39, 66, 45, 33, 59, and 68. In respect to primary prevention of cervical cancer, acceptance of anti-HPV vaccination appeared to decrease over time (from 85-89.9% annually during 2005-2008 to 64.4-60.5% during 2009-2010, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|